Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
Express Scripts
Mallinckrodt
AstraZeneca
McKesson

Last Updated: May 17, 2022

CLINICAL TRIALS PROFILE FOR CEFOXITIN IN PLASTIC CONTAINER


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Cefoxitin In Plastic Container

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00186082 ↗ Antibiotics for Postpartum Third and Fourth Degree Perineal Tear Repairs Completed Santa Clara Valley Health & Hospital System N/A 2003-09-01 This study is undertaken to find out whether prophylactic antibiotics can decrease the infection rate in third and fourth degree perineal tear repairs done in the immediate postpartum period.
NCT00186082 ↗ Antibiotics for Postpartum Third and Fourth Degree Perineal Tear Repairs Completed Stanford University N/A 2003-09-01 This study is undertaken to find out whether prophylactic antibiotics can decrease the infection rate in third and fourth degree perineal tear repairs done in the immediate postpartum period.
NCT00343317 ↗ Prophylactic Intrapartum Antibiotics and Immunological Markers for Postpartum Morbidity in HIV Positive Women Completed Bristol-Myers Squibb N/A 2003-02-01 Postpartum infections are among the leading causes of maternal mortality world-wide, particularly in under-resourced countries. Available data suggests that HIV infected women are at greater risk of postpartum complications than uninfected women. In South Africa, HIV/AIDS and related infections are now cumulatively the leading causes of maternal deaths (though indirectly), with puerperal sepsis among the 5 most common causes. This was a prospective longitudinal cohort of HIV infected (n = 675) and uninfected (n = 648) women. These were women in whom vaginal delivery was anticipated, and were recruited at > 36 weeks of gestation during the antenatal period. Hypothesis - HIV infected women are at increased risk of postpartum infectious morbidity and this morbidity can be reduced by use of prophylactic intrapartum antibiotics.
NCT00343317 ↗ Prophylactic Intrapartum Antibiotics and Immunological Markers for Postpartum Morbidity in HIV Positive Women Completed University of KwaZulu N/A 2003-02-01 Postpartum infections are among the leading causes of maternal mortality world-wide, particularly in under-resourced countries. Available data suggests that HIV infected women are at greater risk of postpartum complications than uninfected women. In South Africa, HIV/AIDS and related infections are now cumulatively the leading causes of maternal deaths (though indirectly), with puerperal sepsis among the 5 most common causes. This was a prospective longitudinal cohort of HIV infected (n = 675) and uninfected (n = 648) women. These were women in whom vaginal delivery was anticipated, and were recruited at > 36 weeks of gestation during the antenatal period. Hypothesis - HIV infected women are at increased risk of postpartum infectious morbidity and this morbidity can be reduced by use of prophylactic intrapartum antibiotics.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Cefoxitin In Plastic Container

Condition Name

Condition Name for Cefoxitin In Plastic Container
Intervention Trials
Urinary Infection 1
Biliary Infection 1
Obese 1
Urinary Tract Infections 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Cefoxitin In Plastic Container
Intervention Trials
Infections 4
Infection 4
Communicable Diseases 4
Urinary Tract Infections 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Cefoxitin In Plastic Container

Trials by Country

Trials by Country for Cefoxitin In Plastic Container
Location Trials
United States 23
France 5
Australia 2
Canada 2
Portugal 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Cefoxitin In Plastic Container
Location Trials
New Jersey 2
California 2
Virginia 1
Kentucky 1
Georgia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Cefoxitin In Plastic Container

Clinical Trial Phase

Clinical Trial Phase for Cefoxitin In Plastic Container
Clinical Trial Phase Trials
Phase 4 4
Phase 3 1
Phase 2/Phase 3 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Cefoxitin In Plastic Container
Clinical Trial Phase Trials
Completed 5
Terminated 4
Unknown status 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Cefoxitin In Plastic Container

Sponsor Name

Sponsor Name for Cefoxitin In Plastic Container
Sponsor Trials
Central Hospital, Nancy, France 2
Assistance Publique - Hôpitaux de Paris 2
The University of Queensland 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Cefoxitin In Plastic Container
Sponsor Trials
Other 73
Industry 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Medtronic
Colorcon
Boehringer Ingelheim
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.